logo
Taking on Goliath: Brain surgeon's clash with UnitedHealthcare shows insurer's hardball tactics

Taking on Goliath: Brain surgeon's clash with UnitedHealthcare shows insurer's hardball tactics

NBC News20-06-2025
U.S. news
A massive hack of the insurance giant set off a chain of events that has left some doctors' practices on financial life support.
June 20, 2025, 6:00 AM EDT
By Gretchen Morgenson
Dr. Catherine Mazzola, a pediatric neurosurgeon, runs a practice in New Jersey that treats low-income children on Medicaid. Since 2008, she has cared for boys and girls with cerebral palsy, spina bifida and other neurological disorders.
But now, her practice is in serious jeopardy, she says, because of recent moves by the insurance and health care giant UnitedHealth Group.
The story begins in February 2024, when a unit of UnitedHealth experienced a massive hack. The unit, Change Healthcare, shuttered its systems and halted all reimbursements owed to hospitals and doctors like Mazzola.
To help providers stay afloat, Optum, another UnitedHealth subsidiary that includes a bank, began offering " temporary," no-interest loans. Mazzola's practice was among those tapping into the program — it received $535,000, documents show.
The practice began repaying the loans, but in January Optum demanded that it repay the money in full and within five business days.
'Our practice is doing the BEST we can,' Mazzola wrote in an email to Optum on Jan. 20. 'Please ask the loan collection people to STOP. We are already in repayment at the maximum possible amount monthly.'
The situation soon got worse. In mid-February, she stopped receiving reimbursements from UnitedHealthcare. By April, her practice was out $78,000, her accountant's records show, and was struggling to make payroll.
Mazzola dug into the UnitedHealthcare claims and was shocked to find the insurer had drawn up reimbursement checks payable to her practice and then deposited those checks into its own bank account, records shared with NBC News show.
'They are trying to bankrupt our practice,' Mazzola said. 'Now, we're going to do brain surgery and instead of paying us, they're going to take the money themselves.'
Bryan Fisher, a spokesman for UnitedHealth Group, the conglomerate that owns the insurer, declined to comment on its actions related to Mazzola's practice, New Jersey Pediatric Neuroscience Institute.
Her case sheds light on something few patients know about: the behind-the-scenes battles doctors say they must wage with insurers over reimbursements and the increasingly aggressive tactics taken by huge payers like UnitedHealthcare.
Her experience also gives credence, antitrust experts say, to concerns that UnitedHealth Group's acquisitions of an array of health care operations in recent years have given it too much power over patients and the doctors treating them.
'You've got physicians looking out for hundreds and thousands of families, and you've got this big corporate entity exerting as much financial power as it can, just because it can,' said Josh Bengal, staff counsel at the Medical Society of New Jersey. 'It's upsetting.'
'$0 in your bank account'
The hack in February 2024 affected 190 million patients, making it the largest ever involving medical data. UnitedHealth Group ultimately paid a $22 million ransom to the cybercriminals.
After the pause in reimbursements, many providers took out loans through Optum — over $9 billion was borrowed, according to company filings.
Repayment terms on the loans were vague, with Mazzola's contract noting only that her practice would have to repay the loan within 30 business days of receiving notice from UnitedHealth Group.
But Mazzola and other doctors said they were assured by the congressional testimony of Andrew Witty, UnitedHealth Group's former chief executive, who said in May 2024 that the company would seek repayment only when borrowers' businesses were back to normal.
Even though Change Healthcare said it restarted claims processing about a month after the breach, doctors who spoke with NBC News said their operations continued to struggle long after, with some saying they are out millions as a result. Others were forced to close after being crippled by the loss of income.
When Optum began demanding repayment of loans in January, it gave borrowers five business days, according to letters reviewed by NBC News. Those who didn't meet the demands could have their UnitedHealthcare reimbursements withheld as repayment, the letters say.
Mazzola's practice had promised to submit $10,000 a month until her $535,000 loan was repaid. It was all she could afford, she told Optum in emails reviewed by NBC News.
Mazzola said an Optum executive told her by phone that her repayments weren't enough. And in mid-February, UnitedHealthcare began intercepting reimbursements owed to Mazzola's practice 'to repay amounts owed under your agreement with Change Healthcare Operations LLC,' documents show.
Upon further investigation, Mazzola learned the puzzling way UnitedHealthcare diverted the money — drawing up checks payable to Mazzola's practice and then depositing them into a UnitedHealthcare bank account, the documents show.
'How can United Healthcare claw back money that we are due for surgeries and office visits?' Mazzola wrote to an Optum executive she had been dealing with.
She received no response, but in April the company stopped seizing reimbursements from her practice after she complained to the American Medical Association.
It waded into the fight on April 11, when Dr. James Madara, the AMA's chief executive, wrote to Roger Connor, the chief executive of Optum Insight, asking that the company stop its payment demands.
'Physician practices are still suffering severe financial distress as a result of the cyberattack nearly 14 months after the breach was first discovered,' Madara wrote. 'We want Optum to honor its commitment to wait to recover repayment for any loans until the physician determines that it is the appropriate time, because the physicians have relied on Optum's statements.'
In a statement, Optum said it is working with providers 'to identify flexible repayment plans based on the individual circumstances of providers and their practices.'
'We have also worked with UnitedHealthcare to ensure the claims it receives are reviewed in light of the challenges providers experienced, including waiving timely filing requirements for the plans under its control,' it added.
Multiple lawyers interviewed by NBC News reviewed the loan agreement Mazzola's practice signed and characterized it as a contract of adhesion — in which one party calls the shots and the other has little choice but to agree. The financial ruin Mazzola and other doctors faced because of the hack, an event caused by inadequate security at Change Healthcare, made the loans even more one-sided, some lawyers said. As a result, doctors may have legal recourse after the aggressive actions UnitedHealth Group took to extract loan repayments.
The central question surrounding UnitedHealth Group's reimbursement actions is 'whether they abused their use of this remedy by insisting on repayment before it was appropriate for them to do so given the damages that they caused,' Daniel Schwarcz, a professor at the University of Minnesota law school, said in an email.
Amid its clashes with doctors, UnitedHealth Group announced earnings of $9 billion from operations in the first quarter of 2025, a 15% jump from the same period last year. Revenue for the three months was $110 billion.
Even after Change Healthcare restarted claims processing, doctors who spoke with NBC News said they were never reimbursed for many claims because the disruption meant they couldn't submit them within insurers' required time periods. The doctors also said their costs increased after the hack because they had to pay staff members to chase reimbursements.
Mazzola, who estimates that her practice lost $1 million because of the hack, has asked Optum to reimburse her for costs her practice incurred as a result of the breach. But the terms Optum offered would have barred her from being able to sue it because of the hack. So she declined to accept it.
'I really believed that Optum, who was orchestrating these loans, would give physicians and physician groups a reasonable amount of time to repay the loans with the understanding that this financial crisis almost bankrupted us,' Mazzola said. 'I mean literally, you're talking about $0 in your bank account, and you have 70 employees to pay.'
Delays of patient care Doctors say they weren't the only ones hurt by the hack. Patients, too, were harmed when providers didn't have the reimbursement revenue needed to buy medicine, for example.
'There were a lot of delays of patient care as a result of it,' said Dr. Pruvi Parikh, an allergist and immunologist in New York City who is medical director of a practice with six locations in New York and 15 in New Jersey.
Parikh's group borrowed $400,000 from Optum to survive the hack. By the end of 2024, it had repaid all but $102,000 of it, documents show.
On Jan. 7, Optum threatened to withhold reimbursements to Parikh's practice if the rest of the loan wasn't repaid in days, an email shows.
'Coming up with that amount of money in five business days is not possible for the majority of private practices,' Parikh said in an interview. 'Not only did they not give us time to get back on our feet, they were like, 'Pay it now.''
While the practice met Optum's demand, she estimated it is out $2 million because of the hack.
In a statement, Change Healthcare said it started clawing back funding it had provided 'more than one year post the event and with services restored.' The company said it is reaching out to those 'that have not been responsive to previous calls or email requests for more information.'
The main reason doctors like Parikh and Mazzola are in this crucible, antitrust experts and physicians say, is that UnitedHealth Group operates so many cogs in the nation's health care machinery. By acquiring an array of health care operations in recent years—including physician practices and pharmacy benefits management, technology, claims processing and financial services — UnitedHealth Group can exert market muscle over weaker participants like doctors and patients.
Federal antitrust lawyers concerned about possible monopolistic activities have sued health care companies in recent years. In 2022, two years before the Change Healthcare hack, the Justice Department and the states of New York and Minnesota sued to stop UnitedHealth Group's acquisition of the claims processor, saying it would reduce competition in health care insurance markets.
Because Change Healthcare dominates the claims clearinghouse business, the government argued, its purchase by UnitedHealth Group would give the conglomerate information about how rivals' insurance plans work, a competitive advantage.
UnitedHealth disagreed, saying it had strong 'firewalls' between units that would prevent sensitive data from being shared throughout the company. Optum, the subsidiary that now houses Change Healthcare, would protect external customers' data from being shared with UnitedHealthcare or its affiliates if the deal went through, the company said.
That argument seemed to persuade the federal judge hearing the case in Washington, D.C., a Trump appointee. In his October 2022 decision greenlighting the $13 billion Change acquisition, U.S. District Judge Carl J. Nichols cited the company's data-sharing firewalls as weighing 'strongly against the government's position.'
Now, doctors say UnitedHealthcare's diverting reimbursements to repay Optum loans shows the kind of data-sharing the government was concerned about.
Hayden Rooke-Ley is senior fellow for health care at the American Economic Liberties Project, a nonprofit, nonpartisan organization that works to curb monopolies. He said UnitedHealth Group's seizure of doctors' reimbursements is an example of what happens when a company coordinates among its different subsidiaries for its own purposes.
'These are the sorts of conflicts of interest we worry about when an insurance company also owns the payment pipes and a bank,' Rooke-Ley said in an interview.
Asked to respond to the criticism, Fisher of UnitedHealth Group declined.
When it added Change Healthcare to its operations in late 2022, Optum said the combined companies would 'benefit the entire health system, resulting in lower costs and a better experience for all stakeholders.'
Parikh, the New York City allergist and immunologist, begs to differ.
'It was a complete disaster, and to this day it's not corrected,' she said of the hack. 'But there hasn't been any accountability to this goliath Optum.'
Gretchen Morgenson
Gretchen Morgenson is the senior financial reporter for the NBC News Investigative Unit. A former stockbroker, she won the Pulitzer Prize in 2002 for her "trenchant and incisive" reporting on Wall Street.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Forget Ozempic and Mounjaro, this firm is on the edge of a weight-loss breakthrough
Forget Ozempic and Mounjaro, this firm is on the edge of a weight-loss breakthrough

Telegraph

time6 hours ago

  • Telegraph

Forget Ozempic and Mounjaro, this firm is on the edge of a weight-loss breakthrough

Questor is The Telegraph's stock-picking column, helping you decode the markets and offering insights on where to invest. This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough action on drug pricing and tariffs have fuelled nervousness, while recently agreed cuts to Medicaid in the 'big beautiful bill' are also causing concern. But medicine will always be a priority for the sick, and innovations from the pharmaceutical industry are vital for creating healthier societies as populations age. Biotech giant Amgen looks particularly well placed to weather current uncertainties and prosper from the long-term prospects of its industry. A first-class dividend record, which includes increased payouts in each of the last 13 years, is testament to the resilience of the business. Key to this is that unlike many rivals, no one product dominates Amgen's $33.4bn (£24.7bn) of sales. In fact, the company boasts 14 blockbuster drugs with over $1bn sales each. This product diversity means that while its biggest selling treatment – an osteoporosis drug called Prolia that generated $4.4bn revenues last year – is expected to see rapid declines following its loss of patent protection in February, the company's top line is forecast to grow. The drugs Amgen sells cover a number of different areas, including cancer, cardiovascular disease, osteoporosis and rare diseases. Recent trading has been strong, too, with 21 drugs reporting record sales last year and 14 reporting double-digit growth. Amgen is experiencing particularly strong growth from cholesterol drug Repatha, which is forecast to net $2.8bn this year, and osteoporosis treatment Evenity, both of which target underserved patient groups. Sales are also soaring for cancer drug Blincyto. In terms of the problems posed by Trump, Amgen looks well placed. Tariffs should not be a major issue given it mostly manufactures in the US, where it is currently increasing capacity. Having just opened a new facility in Ohio, it plans to plough another $900m into growth in the state and a further $1bn is being spent building in North Carolina. Much of this spending is aimed at increasing production of biosimilars, which are lower cost versions of existing drugs that have lost patent protection. This focus should help position the group to deal with the US government's drug-pricing agenda because biosimilars help lower healthcare costs. Amgen has said Medicaid cuts could have a material adverse impact on some drug sales, however, the cuts passed in the big beautiful bill last week were scaled back in order to get it approved. Reassurance about prospects can also be taken from the number of top fund managers backing the stock – all among the best-performing 3pc globally according to financial publisher Citywire. A total of 14 of these individuals back the shares. The level of smart-money backing has won Amgen a place in Citywire's Global Elite Companies index, which is home to the 76 very best ideas from among the c.6,000 stocks held across the portfolios of the top managers Citywire tracks. For these backers, the potential of Amgen's drug development is a key part of its attraction. Investors have been particularly excited about a long-lasting obesity drug Amgen has begun late-stage phase III trials for, called MariTide. It produces similar levels of weight-loss as Wegovy and Zepbound, which are multibillion-dollar treatments made by Novo Nordisk and Eli Lilly respectively, but MariTide only needs to be injected once a month or less, compared with weekly for the existing drugs. While the potential is exciting, the market reacted negatively to recent news of high levels of nausea during early use. Amgen reckons it can address this by starting patients on lower doses. Better trial news has recently come from cancer treatments, specifically a stomach cancer drug called Bemarituzumab. Amgen is also looking to extend the uses of some of its existing blockbuster medicines. The company put a record $6bn into research and development last year pursuing new opportunities, which represented more than 18pc of sales and a 25pc increase on 2023. While Amgen's margins have nudged down over recent years, it is nevertheless highly profitable. It reported 46.9pc underlying operating margins last year. Meanwhile, solid earnings per share growth is predicted over the next two years of just over 4pc on an annualised basis. That looks an attractive package with the shares priced at 14 times forecast earnings and yielding 3.4pc, especially once the potential for positive surprises from the busy development pipeline is factored in. British buyers of the shares need to fill out the correct paperwork to minimise withholding taxes and check for any extra dealing costs with brokers. Questor says: buy Ticker: NYSE:AMGN

Trump's ‘Big Beautiful Bill' is estimated to leave millions without health care. He insists ‘it's not going to cause death'
Trump's ‘Big Beautiful Bill' is estimated to leave millions without health care. He insists ‘it's not going to cause death'

The Independent

timea day ago

  • The Independent

Trump's ‘Big Beautiful Bill' is estimated to leave millions without health care. He insists ‘it's not going to cause death'

President Donald Trump defended his 'Big, Beautiful, Bill' during a Fox News interview broadcast on Saturday night, claiming "it's not going to cause death, it's going to keep people alive" even as millions are estimated to lose health coverage under the legislation signed into law on July 4. About 11.8 million people are at risk of losing their health insurance, according to the Congressional Budget Office, but not all at once. The legislation cuts federal health care programs over the course of a decade to remove close to $1 trillion from Medicaid, Obamacare, and the Children's Health Insurance Program. Earlier this month, the House voted 218 to 214 to pass the bill after Vice President JD Vance had to break a tie in the Senate to get it passed. The cuts to healthcare benefits were made to pay for tax cuts that mainly benefit the wealthy, an extension of Trump's 2017 tax cuts, which were set to sunset at the end of 2025. The CBO estimates that the bill will add $3.4 trillion to federal deficits over the next 10 years, a forecast rejected by many congressional Republicans and the White House. Medicaid provides health care sponsored by the government to low-income and disabled Americans. The new legislation enacts work requirements for some able-bodied adults and more eligibility checks. The president called on Republicans to 'explain the bill because it's so big and so good,' while blasting Democrats for only doing one thing well — 'complain.' 'I tell Republicans, you have to speak positively about it,' the president said in an interview with his daughter-in-law, Fox News' Lara Trump. 'The Democrats, they only do one thing good, and that's complain, and they say it's going to cause death, and this and that … it's a sound bite. Somebody gave them a sound bite,' Trump added. 'It's not going to cause death. It's going to keep people alive, and it's going to make our country successful,' he said. Trump claimed that the bill has already led to major investments. 'We are getting investment because of that bill. We're having investment made in this country that nobody's ever believed. We're up to close to $15 trillion,' he claimed. 'We're having car companies come in and build their plants here, which they wouldn't have even thought about. They would have never done it,' he added. The president went on to call AI 'the big hot thing,' claiming that trillions of dollars were being spent in the industry. 'They wouldn't have done that without what we just did last week,' he said.

US judge stands by move to block cutting off of Planned Parenthood's Medicaid funding
US judge stands by move to block cutting off of Planned Parenthood's Medicaid funding

Reuters

time2 days ago

  • Reuters

US judge stands by move to block cutting off of Planned Parenthood's Medicaid funding

BOSTON, July 12 (Reuters) - A federal judge is standing by her decision to block the implementation of a provision in U.S. President Donald Trump's recently passed tax and spending bill that would prevent Planned Parenthood health centers from receiving Medicaid funding. The Trump administration on Friday asked U.S. District Judge Indira Talwani in Boston to dissolve what it called a "highly unusual" temporary restraining order she issued hours after Planned Parenthood sued over the law on Monday. The administration said Talwani's brief order provided no explanation for why she was blocking part of the One Big Beautiful Bill Act the Republican-led Congress passed that bars health care providers like Planned Parenthood's clinics that offer abortions from receiving Medicaid reimbursements. Talwani, an appointee of Democratic President Barack Obama, responded late Friday that such an order was necessary to prevent disruptions to health care until she could hear arguments on July 18. But in light of the Trump administration's request, she issued a new, amended temporary restraining order, opens new tab making clear that she had concluded Planned Parenthood was likely to succeed in proving the law violated the U.S. Constitution. Planned Parenthood and the U.S. Department of Justice did not respond to requests for comment. Under the law, Medicaid funds cannot go to "prohibited" entities, certain nonprofits that provide abortion services, and their "affiliates". Planned Parenthood has said the law was drafted to specifically target its members and would have "catastrophic" consequences for its nearly 600 health centers if implemented, putting nearly 200 of them in 24 states at risk of closure. Talwani said the bar on funding to affiliates created confusion among members of Planned Parenthood Federation of America, the parent organization, that do not themselves qualify as prohibited entities, such as clinics that do not provide abortion services due to state-level bans. Talwani said as a result, the law burdened the right of Planned Parenthood's 47 members to associate with each other and their parent organization, which advocates in favor of reproductive health care policies, in likely violation of the U.S. Constitution's First Amendment. "The Supreme Court has 'long understood as implicit in the right to engage in activities protected by the First Amendment a corresponding right to associate with others' in pursuit of desired political, educational, or social ends," she wrote, citing a 1984 Supreme Court ruling.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store